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ABSTRACT
Development of predictive in vitro assays for early toxicity evaluation is
extremely important for improving the drug development process and
reducing drug attrition rates during clinical development. High-content
imaging-based in vitro toxicity assays are emerging as efficient tools for
safety and efficacy testing to improve drug development efficiency. In
this report we have used an induced pluripotent stem cell (iPSC)–derived
hepatocyte cell model having a primary tissue-like phenotype, unlimited
availability, and the potential to compare cells from different individ-
uals. We examined a number of assays and phenotypic markers and
developed automated screening methods for assessing multiparameter
readouts of general and mechanism-specific hepatotoxicity. Endpoints
assessed were cell viability, nuclear shape, average and integrated cell
area, mitochondrial membrane potential, phospholipid accumulation,
cytoskeleton integrity, and apoptosis. We assayed compounds with
known mechanisms of toxicity and also evaluated a diverse hepato-
toxicity library of 240 compounds. We conclude that high-content au-
tomated screening assays using iPSC-derived hepatocytes are feasible,
provide information about mechanisms of toxicity, and can facilitate the
safety assessment of drugs and chemicals.
INTRODUCTION
T
he pharmaceutical industry continues to face challenges
associated with attrition of drug candidates late in the de-
velopment pipeline, or drugs being withdrawn after ap-
proval.1 Drug safety is one of the primary concerns of drug
development and liver toxicity is among the top organs for adverse
drug reactions. In fact, drug-induced liver injury has been associated
with over a third of acute liver failures in the United States and more
than 1,000 drugs are considered potentially toxic to the liver.2,3
Drug-induced liver injury is one of the major causes of drug candi-
date failure in preclinical and clinical testing4 and is also the most
frequently cited reason for withdrawal of approved drugs.5,6
While in vivo animal studies remain the standard for toxicity
testing, they are time consuming and costly, and more importantly,
are rather poor predictors of human toxicity.7,8 There is also growing
momentum to move away from animal models for toxicity testing
and toward cell-based in vitro assays.9,10 Predictive in vitro cell-
based assays should reduce or obviate the dependence on animal
models, streamline the assessment of candidate molecules and their
metabolites, and facilitate evaluation of the mechanisms of toxicity,
kinetics, and dose-responses. In addition, cell-based toxicity models
will reduce per compound assay cost and thereby enable deployment
earlier in the development process and allow focus on larger number
of compounds.
A number of in vitro models have been established for hepato-
toxicity testing.11,12 For example, precision-cut liver slices13,14
contain all cell types of the liver in their natural architecture and have
xenobiotic metabolism capacity. This model, however, is arguably
not well suited for high-throughput studies. Immortalized cell lines,
such as HepG2, and more recently HepaRG cell line,15 are also widely
employed. Cultures of primary (e.g., freshly isolated or cryopre-
served) human, rodent, or canine hepatocytes have also been widely
used for in vitro testing.16 However, high inter-individual variability,
limited availability, high cost, and changes in cell morphology and
liver-specific functions during long-term culture are significant
limitations.
Human induced pluripotent stem cell (iPSC)–derived hepatocytes
show great promise with respect to having a primary tissue-like
phenotype, consistent and unlimited availability, and the potential
to establish genotype-specific cells from different individuals.17
iPSC-derived tissue specific cells provide relevant human biology
in vitro and are increasingly being studied for their potential to ac-
curately predict drug-induced toxicity.18–21 As a result, iPSC-derived
cell models are being adopted by the pharmaceutical industry for
preclinical toxicity studies.22,23 To realize the full potential of iPSC-
derived cell models, it is necessary to develop predictive in vitro
assays that can be performed in a high-throughput manner. To that
end, we have developed several assays for measuring general and
mechanism-specific hepatotoxicity that are well-suited for auto-
mated analysis.
High-content imaging-based in vitro toxicity assays show promise
for safety and efficacy testing as they can be performed using high-
throughput systems for simultaneous screening of many
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compounds.24 High-content imaging has been used with
primary hepatocytes15 and immortalized cell lines.16,25,26
In these studies, hepatotoxicity was evaluated using
morphological and biochemical readouts, including cell
count, nuclear shape, mitochondria potential (MP), Ca2 +
content, and cell permeability.
Given the promise of both iPSC-derived hepatocytes
and high-content screening, we developed imaging and
analysis methods that provide tools for characterization
of multiple toxicity phenotypes using live cells. Specifi-
cally, we characterized a number of toxicity assays and
phenotypic read-outs, including characterization of cell
shape, cell adhesion and spreading, nuclear condensa-
tion, accumulation of lipids, cytoskeleton integrity, in
addition to short-term and long-term changes of MP. To
improve assay workflow, we have optimized certain
protocols that can be used as one step staining, reducing
assay time and minimizing cell disturbance. In addition,
by taking advantage of high-content image acquisition
systems with large field of view cameras and improved
image analysis software, we demonstrate that the anal-
ysis results can be reported in real-time. Finally, we have
tested a commercially available library of compounds
that have been shown to be hepatotoxic. The results il-
lustrate that this method has significant promise for




The cell model used for all assays were iCell hepa-
tocytes (Cellular Dynamics International [CDI], Madison
WI), which are human iPSC-derived hepatocytes. Cells
were received fresh and processed according to the pro-
tocol provided by CDI. Briefly, live cells were dis-
aggregated by trypsinization and purified over a density
gradient and then plated onto collagen-coated plates of
the appropriate format using the plating and mainte-
nance media outlined in the protocol from CDI. Char-
acterization of the cells is shown in Figure 1 and included
morphological and histochemical staining analyses and
albumin production as measured by ELISA using Albu-
min ELISA Quantitaion Set, #E80-129 (Bethyl Labora-
tories, Montgomery, TX) read at 48 h in culture.
Morphology characteristic of hepatocytes was displayed upon plat-
ing and images captured at 96 h postplating were observed to contain
bi-nucleation and bile canalicular formation. PAS staining (#P5463;
Sigma-Aldrich, St. Louis MO) was positive and indicative of glycogen
storage activity. Oil red (#O0625; Sigma-Aldrich) and BODIPY
staining showed evidence of lipid uptake. Albumin staining was done
using anti-albumin antibodies (Cedar Lane) and secondary antibody
donkey anti-mouse-AlexaFluor488 (Invitrogen, Carlsbad, CA). All
images shown were taken with a 10· objective.
Cell Culture and Compound Treatment
Cells were plated at a density of 60,000 cells/well (96-well plate) or
15,000 cells/well (384-well plate) on black clear bottom collagen-coated
plates (BD Biosciences, San Jose, CA) and incubated at 37C and 5% CO2
for 2 days in media containing glucose (media D) prior to compound
treatment. We have used cell plating densities recommended by CDI
protocol. In addition, we have found that using lower plating density
(12,000 cells/well, 384-well plate) resulted in sub-confluent cell
monolayer, while higher densities (18,000 cells/well) resulted in over-
confluent cell culture. Cells were observed to exhibit a uniform
Fig. 1. Morphological and functional characterization of iCell hepatocytes. (A)
Transmitted light image of iCell hepatocytes after 4 days in culture. Binucleation
is indicated by circles and bile canaliculi by arrows. (B) Indication of levels of
albumin production (pg), glycogen storage (periodic acid Schiff PAS staining),
and lipid accumulation (Oil Red and BODYPY staining).
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confluent monolayer with cobblestone-like morphology (Fig. 1A). The
media was then switched to a glucose-free, galactose-containing solu-
tion for 24h (all media formulations provided by CDI). Dilutions of
individual compounds were prepared from 100mM dimethyl sulfoxide
(DMSO) stock solutions. Final DMSO concentration in the media was
0.1%. Compounds were tested in quadruplicate in a dilution series by
half-log concentration increments over a range of 10nM–1,000mM.
Compounds from the hepatotoxicity library were prepared from 10mM
DMSO stocks and tested at five concentrations ranging from 1 to
100mM. For the multiparameter toxicity assay, cells were treated with
compounds for a 72h period at 37C and 5% CO2. For the measurement
of MP by the addition of JC-10 dye, the cells were treated for 60min. For
the autophagy and phospholipidosis assays, the cells were incubated at
37C and 5% CO2 for 24 or 48h.
Assessing Multiple Parameters for Hepatotoxicity
Using Fluorescent Probes
Several fluorescent probes were simultaneously used to monitor
cells in culture. Calcein AM (Invitrogen) was used as a marker of cell
viability, cytoskeleton and cell area (total cell count). Hoechst 33258
(Invitrogen) was used to evaluate nuclear shape. MitoTracker Orange
CM-H2TMROS (Invitrogen) served as a marker of the MP. For live cell
imaging assays, cell media was removed and cells incubated with a
mixture of the following reagents in phosphate-buffered saline
(PBS): 1 mM Calcein AM, 2 mg/mL Hoechst 33258, and 200 nM of
MitoTracker Orange for 30 min at which point the staining solution
was replaced with PBS containing 0.1% of fetal bovine serum (FBS;
Gibco, Invitrogen) and images were acquired using the ImageXpress
Micro XL system (Molecular Devices, LLC, Sunnyvale, CA) with a
10· or 4· objective. No additional washes were necessary to obtain
high quality images by this protocol. During acquisition, plates were
controlled at 37C. We found that stained plates are stable for at least
90 min after staining. The number of viable cells in control samples
and staining intensities were very similar at 30 min and 120 min
poststaining, while after 3 h those parameters had decreased >30%.
For the fixed cell imaging protocol, the cell culture medium was
removed and cells were incubated first with the mix of Hoechst 33258
(2mg/mL) and MitoTracker Orange (200nM) for 30min, then the cells
were fixed using formaldehyde (4% final concentration; Sigma-Aldrich)
in PBS for 15min at the room temperature. Fixed cells were then washed
once with PBS, once with permeabilization solution and permeabilized
for 1h using 0.02% saponin (Sigma-Aldrich) plus 2% FBS. After per-
meabilization the cells were stained with AlexaFluor-488 (AF488)-
conjugated phalloidin (Invitrogen) for 2 h at room temperature. Note
that this step may be combined with the permeabilization step if desired.
Cells were washed twice with PBS before images were acquired. It should
also be noted that fixing the cells and phalloidin staining could be done
after the live cell imaging protocol with Calcein AM, if the subsequent
evaluation of additional markers or cell storage is desired.
MP Assay
In addition to the multiparameter staining protocol, a MP assay
was also used to further elaborate the toxicity assessment. In contrast
to the 72 h incubation during the general toxicity assay described
above, the MP assay measures rapid (30–90 min) effects of com-
pounds on MP. Cells were treated with compounds for 60 min and
mitochondria membrane potential was monitored by the addition of
the mitochondria active dye JC-10 (AAT Bioquest, Sunnyvale, CA)
following the recommended protocol and appropriate concentrations
of included reagents. Mitochondrial toxicity assays were performed
on separate sets of plates and typically combined with the nuclear
(Hoechst) stain. As the JC-10 staining protocol requires 15–30 min
incubation with reagents, in the typical experiment, a 6· solution of
JC-10 reagent was directly added to the cell culture media without
removal of the compound. The plates were incubated at 37C and 5%
CO2 for 30 min (total time for compound treatment is 60 min), and
then images were acquired using ImageXpress Micro XL system at
37C.
Autophagy and Phospholipidosis Assays
A selected set of compounds were tested for their ability to induce
autophagy and phospholipidosis. Autophagy was assessed by the
Cyto-ID Autophagy Detection Kit (Enzo Life Sciences, Farmingdale,
NY) after treatment of cells with compounds for 24 h. Phospholipi-
dosis was measured using the HCS LipidTOX Phospholipidosis and
Steatosis Detection Kit (Invitrogen) for neutral lipids and phospho-
lipids after treatment of cells with compound for 48 h. Separate assay
plates were used for both autophagy and phospholipidosis assays.
The staining protocol followed the product recommended reagent
dilutions and buffers.
Image Acquisition and Analysis
Images were acquired using the ImageXpress Micro XL system
using 20·/0.45NA ELWD Plan Fluo, 10·/0.3NA Plan Fluor, or
4·/0.2NA Plan Apo objectives. The light source was a solid state
white light engine with emission from 380 to 680 nm. A fluorescein
isothiocyanate (FITC) filter cube (ex 482/35, em 536/40) (center
wavelength [nm]/bandpass width [nm]) was used for Calcein AM,
Cyto-ID, and LipidTOX staining of neutral lipids. A tetramethyl
rhodamine isothiocyanate (TRITC) filter cube (ex 543/22, em 593/40)
was used for MitoTracker Orange and LipidTOX staining of phos-
pholipids. A 40,6-diamidino-2-phenylindole (DAPI) filter cube (ex
377/50, em 447/60) was used for Hoechst nuclear stain. Typically,
one image per well was taken for 384-well plates and two to four
images per well were taken for 96-well plates when using 10· or 20·
objectives. Some assays were done using a 4· objective, in this case
one image per well was taken. The number of images was determined
by a balance of number of cells per field of view and acquisition
time. Multiparameter toxicity assay can be done with either 10· or
4· objectives. A 10· objective provides higher resolution of cells
and subcellular structures while allowing one to capture relatively
large numbers of cells (2,000–3,000) in a single image (27% of the
384-well area and *7% of 96-well area captured in one image).
When using a 4· objective, the image captures an entire 384-well
(>10,000 cells) with sufficient resolution to detect cells and nuclei.
However, detection of nuclear size or cell size is less accurate than
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with 10· magnification. Other assays described here (MP, autophagy,
and phospholipidosis) require at least 10· magnification. 20· mag-
nification provides even better resolution but typically requires
taking multiple sites per well and adds to acquisition time.
Typical exposure times ranged from 10 ms to 100 ms. All image
analysis was done using MetaXpress 4 or MetaXpress 5 software
(Molecular Devices, LLC) and various image processing applica-
tion modules including Multi-Wavelength Cell Scoring, Count
Nuclei, and Granularity. In addition, the Custom Module Editor
(CME) in MetaXpress 5 software was used to combine the above
algorithms into one analysis module and characterize additional
features important for analysis of phenotypic changes associated
with toxicity. The CME algorithm for the general hepatotoxicity
assay involved the following steps: (1) identification of nuclei and
determination of nuclear area; (2) segmentation of cells and de-
termination of cell area; (3) measurement of Calcein AM intensity
in cell area; (4) measurement of MitoTracker Orange intensity in
cell area; (5) determination of nuclear brightness; (6) classifica-
tion of nuclear condensation; and (7) measurement of output
parameters.
Images for the MP assay images were acquired using the TRITC and
FITC channels for JC-10 staining along with a DAPI channel if
Hoechst staining was included. For the phospholipidosis assay, the
TRITC and FITC channels were used for phospholipids and neutral
lipids, respectively. Autophagy was detected using the FITC channel.
Typically one image per well was taken for 384-well plates using 10·
objective for these assays. Images were acquired with 20· objective
when higher resolution and improved analysis of small features such
as granules was desired. Images were analyzed using MetaXpress 4 or
MetaXpress 5 software and the Granularity application module with
or without single cell segmentation based on optional nuclear
staining. A similar image acquisition and analysis setup was used for
the phospholipidosis and autophagy assays.
The statistical analysis included calculation of a Z0-factor coeffi-
cient.27 As used here, it represents the separation of positive and
negative control wells on a given plate. Typically, 8–16 control wells
each for positive and negative are included on each plate, and Z0 =
1 - [(3·rpos + 3·rneg)/j(Mpos - Mneg)j], where r = standard deviation
and M = average value. In certain cases, only four control wells each
were used for controls; these are noted in the text.
Compound Library Screening
The Screen-Well Hepatotoxicity Library (Enzo Life Sciences)
contains 240 compounds including anti-cancer, anti-inflammatory,
neuroleptics, antibiotics, and other classes of compounds. Major
toxicity categories include steatosis, cholestatic effects, mitochon-
drial toxicity, CYP450 inactivation, toxic metabolites, Mallory body
formation, and elevation of liver enzymes. In addition to hepatotoxic
compounds, the library contains 30 control compounds that have no
reported liver toxicity. Two wells were blank. Therefore, the library
contains 208 hepatotoxic compounds and 30 negative (‘‘hepato-
safe’’) compounds. The compounds were dissolved in DMSO at 10 mM
and aliquoted into deep-well plates.
Cells were treated with library compounds for 72 h in a 384 well
format plate in duplicate. In addition, each plate contained 48 vehicle
only wells treated with the corresponding DMSO concentration. Hit
selection criteria were based on a decrease or increase of each mea-
sured response parameter being greater than three standard devia-
tions (SDs) from average DMSO control well response. At least two
parameters were required to respond with a change greater than three
SDs for a compound to be classified as a hit. Based on the toxic
compounds identified by these combined assay measures, the assay
sensitivity was calculated as the percentage of positive compounds
out of the total number of compounds expected to be positive (208
hepatotoxic compounds). Assay specificity was calculated as per-
centage of negative compounds out of the total number of com-
pounds expected to be negative (30 safe compounds). The predictive
value of the assay was calculated as the mean value between sensi-
tivity and specificity.
Concentration-Response Curve Fitting, Derivation
of Benchmark Concentrations and Ranking of Compounds
Normalized (to corresponding DMSO-containing wells) data for
each chemical and endpoint were used to fit a concentration-
response quantitative logistic function and to visualize the concen-
tration–response relationship, using the R software version 2.15.2.
Variability of the DMSO-only wells was used to derive the benchmark
concentration (BMC),28 which involves modeling to obtain dose
levels corresponding to specific response levels near the low end of
the observable range of the data. An accepted approach for contin-
uous data is to define a point-of-departure (i.e., benchmark) response
as a change in the mean equal to one control SD from the control
mean. An interactive Toxicological Prioritization Index (ToxPi)
application29 was used to integrate evidence across endpoints and to
visualize the relative prioritized ranks of compounds.
RESULTS
Characterization of Human iPSC-Derived Hepatocytes
Human iPSC can be developed from adult tissue via noninvasive
methods, expanded indefinitely, and differentiated into multiple cell
types.30,31 The iCell hepatocytes used in the studies were provided as
a fully differentiated and highly pure population of cells that formed
an adherent cell monolayer with a cobblestone morphology similar to
primary human hepatocytes (Fig. 1A). Purity was measured by
counterstaining for iPSC markers; typically less than 5% of the
population is found positive for iPSC markers (data not shown32). The
cells have round nuclei, distinct nucleoli, and a high cytoplasm to
nuclear ratio. In addition, as indicated in Figure 1A, some of cells
show bi-nucleation (circles), and visible evidence of bile canaliculi
(arrows). iCell hepatocytes express multiple hepatocyte markers,
including albumin, alpha-1-antitrypsin, and HNF4a protein (not
shown). In addition, iCell hepatocytes secrete albumin at a level
similar to primary human hepatocytes and greater than HepG2 cells,
exhibit glycogen storage, lipid accumulation, and tight junction
formation (Fig. 1B). We have confirmed that incubation of cells in
galactose media does not perturb their phenotype or ability to
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secret albumin. Such characterization was done by immunostaining
followed by imaging with a 10· objective (data not shown).
Multiparameter Assays for Hepatotoxicity
The primary goal of this study was to evaluate and optimize sev-
eral assays to test for general and mechanism-specific hepatotoxic-
ity. We posit that a mixture of three dyes provides phenotypic
readouts indicative of general cellular toxicity that occurs through
various pathogenetic mechanisms. The phenotypic readouts include
cell viability assessment and characterization of cell area (by Calcein
AM), MP (by MitoTracker Orange), and total cell count along with
nuclear characterization by area and fluorescence intensity (Hoechst
stain). Advantages of this method, especially for screening envi-
ronments, include simplicity, cost, and ease of workflow. Cell
staining is performed by adding a mix of dyes in one step, without
fixing cells or repeated washes. This procedure minimizes automa-
tion steps required and reduces cell losses by washes that may lift off
loosely attached cells and impact assay quality. Representative
composite images of cells treated with amitriptyline from this assay
are shown in Figure 2A.
For a more in-depth investigation into cytotoxic mechanisms
elicited by the compounds assayed, several analyses were run in
parallel to fully characterize phenotypic changes detected. Images
were first segmented into individual cells by nuclear staining and
then standard cell segmentation algorithms were used to associate
specific image areas with each cell (Fig. 2B). Cell segmentation based
on nuclei worked very efficiently for confluent cells and allowed the
scoring of cells as positive or negative for additional markers to
define the total cell number (nuclear count), number of viable cells
(Calcein AM–positive), and cells with intact mitochondria (Mito-
Tracker Orange–positive). In addition to cell scoring and count, this
analysis provided additional parameters, which could be quantified
specifically for each cell or averaged over the entire population in the
image, including average and total cell area positive for Calcein AM
or MitoTracker, average and total fluorescent intensities for Calcein
AM or MitoTracker orange, and average and total nuclear areas and
fluorescence intensities. The nuclear area and intensity was used to
determine the presence of nuclear condensation as evidenced by
increased nuclear brightness and decreased nuclear area (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/adt), which may indicate apoptosis. These
readouts can be used either selec-
tively or in combination for charac-
terizing toxicity effects and
determining concentration-response.
A comparison was made between
characterizing toxicity by use of total
cell count via nuclear stain, live cell
count via Calcein AM, and count of
cells with intact mitochondria via
MitoTracker Orange. Detailed results
of average, SD, Z0-factor coefficient,
and assay window for ten different
output parameters calculated for
nine compounds are given in Sup-
plementary Table S1. The Z0-factor
coefficients for the most robust out-
put parameters (‘‘number of cells
positive for Calcein AM,’’ ‘‘positive
W2’’) were typically > 0.5. For other
parameters, Z0-factor coefficients
were dependent on individual com-
pounds and specific compound ef-
fect: for example, ‘‘all nuclei mean
area’’ was significantly decreased
and Z0-factor coefficients higher for
staurosporine (0.46) and aflatoxins
(0.7), consistent with nuclear con-
densation phenotype. Z0-factor coef-
ficients were > 0.5 for ‘‘positive W2
mean stain area’’ for mitomycin C and
phenylbutasone, indicating decreased
cell spreading (Supplementary Tables
Fig. 2. Live cell imaging toxicity assessment. (A) iCell hepatocytes treated with indicated con-
centrations of amitryptiline for 72 h, then stained with Calcein AM, Hoechst 33258, and
MitoTracker Orange. Images were taken using a 10· objective and analyzed using Multi-
Wavelength Cell Scoring module. (B) Image processing by Multi-Wavelength Cell Scoring appli-
cation module. Masks shown define Calcein AM staining (green), MitoTracker staining (orange),
and Hoechst 33258 staining (grey). (C) Comparison of IC50s obtained by using total cells (nuclear
count, blue circles), Calcein AM–positive cells (green triangles), or MitoTracker Orange–positive
cells (red squares). NT, no significant toxicity detected from the four-parameter curve fit to
the data.
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S1 and S2). The multi-dye assay IC50 values were evaluated for nine
representative hepatotoxic compounds using the three methods (Fig.
2C). The IC50s determined by ‘‘count of cells positive for Calcein AM’’
were generally lower than those determined by ‘‘total cell count’’ for
several compounds, for example, aflatoxin, imatinib, and aphidico-
lin. This can be partially attributed to the fact that, often, dead or
apoptotic cells are still present in an image and contribute to the
nuclear count (Fig. 2A). For other compounds, IC50s determined by
the different readouts were found to be closely correlated (e.g., for
doxorubicin). Several other parameters were defined to assist the
phenotypic characterization of cells. While a decrease in cell number
is a very strong indicator for cytotoxicity, more subtle changes in cell
appearance and morphology may be good early indicators of cell
stress yet are more difficult to quantify. We aimed to detect and
quantify change in appearance as an indicator of cell stress. Figure
3A shows representative images of treated cells that exhibited
changes in average cell area and/or total cell area. Cells treated with
atorvastatin, imipramine, naproxen, or tolcapone did not exhibit a
dramatic decrease in cell number, yet showed a significant decrease
in cell area as a result of rounding or loss of cell–cell contact. Spe-
cifically, cell count in the case of atorvastatin was decreased by only
25%, while total area of viable cells was decreased by 50%. In other
examples (e.g., tomeltin or suldinac), an increase in average cell size
was observed as a result of vacuolization or swelling. In the case of
papaverin treatment, a decrease in average cell size was observed as a
result of reduced cell spreading. Such changes can be quantified
using the total area covered with viable cells or average individual
cell area (Supplementary Fig. S2A). Significantly, changes in these
parameters appear earlier, and can be a more sensitive indicator of
toxicity than live cell count, since cell rounding up or vacuolization
usually appears once the cell has committed, but still prior to cell
death. Therefore, in addition to ‘‘total cell count,’’ ‘‘total’’ or ‘‘inte-
grated fluorescent intensity by Calcein AM’’ and ‘‘total positive cell
area’’ can be used for dose-dependent characterization of compound
effects and determining IC50 values.
Nuclear characterization is another important parameter to assess
cell death, allowing detection of the phenomenon of nuclear con-
densation, usually a hallmark of apoptosis.33 Nuclear condensation
can be characterized by increased
nuclear fluorescent intensity and de-
crease of nuclear area.25 We have
used the nuclear characterization
measures of average nuclear intensity
and nuclear area as additional read-
outs for multiparametric toxicity as-
sessment (see Supplementary Fig.
S2B and Supplementary Table S1).
Images showing this effect for cells
treated with staurosporine and re-
sulting concentration response curves
are shown in Figure 4. This effect was
concentration-dependent, as evident
from Figure 4B. Caspase staining
(CellEvent Caspase 3/7; Invitrogen)
done in parallel with the assay for
staurosporine and anisomycin con-
firmed the presence of apoptosis for
those compounds (data not shown).
Nuclear characterization can provide
additional sensitivity for certain
compounds and does not add appre-
ciable time to the image analysis
process.
In addition to the assays described
above, we evaluated an assessment of
cytoskeleton integrity by phalloidin
staining. Figure 5A shows intact cells
and cells treated with aflatoxin B1.
The cytoskeleton integrity assay can
be combined with Hoechst nuclear
stain and, if desired, with MitoTracker
Orange if the latter is done prior to
Fig. 3. Phenotypic characterization of hepatotoxicity by quantitation of the average and total
stained cell areas. Images of iCell hepatocytes treated with 100 mM of indicated compounds for
72 h, then stained with Calcein AM and Hoechst 33258. Examples presented show impact of
different compounds on total positive cell area and/or average positive cell area. Images were
acquired using a 10· objective.
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cell fixing. Detailed results of average, SD, Z0-factor coefficient, and
assay window for eight different output parameters calculated for
five compounds are given in Supplementary Table S2. The output
parameter with highest Z0-factor coefficients and assay windows was
‘‘count of cells positive for actin staining.’’ This parameter was used
to measure concentration response of six known hepatotoxic com-
pounds (Fig. 5B). The cytoskeleton integrity assay had an excellent
assay window and low variance leading to good 4-parameter fits of
the concentration–response curves for most of the compounds tested.
This assay could be used as a supporting alternative method for
hepatotoxicity measured by Calcein AM. However, it does require the
additional steps of fixing, permeabilizing, and washing the cells. A
distinct advantage is that the assay plates can be stored, providing a
fixed time point for readout if that is desired in a workflow.
In addition, we have evaluated effect of timing of compound ex-
posure on cell viability and other markers. Cells were treated with a
set of hepatotoxic compounds (amiodarone, tamoxifen, pimozide,
mitomycin C, idarubicin, and haloperidol) for 1, 3, or 7 days, on
parallel plates. We have noticed that while some compounds (e.g.,
idarubicin) had comparable effects in all time points, other com-
pounds (e.g., haloperidol) had time-dependent
incremental effect (Supplementary Fig. S1C).
IC50s were apparently smaller for 7 days exposure




In addition to general cellular toxicity assess-
ment, high-content analysis can address other
mechanism-specific types of toxicity, and there
are many reagents available for such assays.
Specifically, we have evaluated the mitochondrial
dye JC-10, Cyto-ID dye, and LipidTOX reagents to
determine the effects of compounds on MP, au-
tophagy, and phospholipidosis/steatosis, respec-
tively.
MP assay. Mitochondrial depolarization is an
early signal for hypoxic damage or oxidative
stress. In addition to the 72 h compound treatment
assay, which can show mitochondrial damage as a
result of cell death caused by various mechanisms,
we performed a short-term (60 min) compound
treatment followed by JC-10 staining in combi-
nation with a nuclear stain. This assay allows
examination of the immediate direct effects of
compounds on MP. Figure 6 shows images of
control cells and cells treated with an inhibitor of
oxidative phosphorylation, antimycin A, and a
dramatic difference in the content of intact mi-
tochondria (orange stain) is observed. We used the
MetaXpress 5 software Granularity application
module for the analysis of mitochondrial damage using the nuclear
stain to define and segment individual cells. The module finds
granules (mitochondria) and allows defining such characteristic pa-
rameters as total number of granules, total granule area, number of
granules per cell, and average intensity of the granules. Detailed
results of average, SD, Z0-factor coefficient, and assay window for
five different output parameters calculated for two compounds are
given in Supplementary Table S4. We found that ‘‘average number of
granules per cell,’’ ‘‘average area of granules per cell,’’ and ‘‘total
number of granules per image’’ all gave a 10· or greater assay
window. Since this assay can be used in real time, we characterized
the compound response at several time points: 60 min, 90 min and
2 h. We found that a 60 min time point gave the most robust results,
while 90, 120, or 180 min time points resulted in decreased signal
intensity. A time course study was done to show effect of compound
incubation time on assay results (Supplementary Tables S5 and S6).
We characterized the assay using a panel of known poisons of oxi-
dative phosphorylation including antimycin A, CCCP, and valino-
mycin. The Z0-factor coefficient for the assay was 0.68. We also tested
various compounds whose expected mechanism of hepatotoxicity is
Fig. 4. Phenotypic characterization of toxicity by nuclear shape and intensity. (A)
Images of iCell hepatocytes treated with 10 mM of staurosporine, stained with Hoechst
33258. Images were acquired using a 10· objective. (B) Concentration-dependent re-
sponses for several compounds using ‘‘average nuclear area’’ as a readout. The IC50s
for the tested compounds were aflatoxin G1 (red squares), 1.9 mM; staurosporine (or-
ange diamonds), 1.9mM; aflatoxin B1 (blue circles), 5.5 mM; idarubicin (grey squares),
7.4 mM, mitomycin C (green triangles), 18 mM; and retinoic acid (purple circles), 482 mM.
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mitochondrial damage (tolcapone, flutamide, nefasodone, le-
flunomide, ketoconasole, isoniazid, and fusariotoxin). Compounds
were tested over a concentration range from 1 nM to 100 mM. The
resulting concentration–response curves for these compounds and
measured IC50 values are shown in Figure 6B.
Autophagy is a process of selective degradation of intracellular
targets such as mis-folded proteins and damaged organelles. This
process is important for maintaining homeostatic function of the cell,
and it may also function as a survival mechanism to maintain via-
bility during periods of stress and a number of drugs have been
shown to increase or decrease autophagy. We have evaluated the
performance of the autophagy assay for high-content analysis. iPSC-
derived hepatocytes were treated with compounds for 24 h, then
stained with Cyto-ID dye plus a nuclear stain and images analyzed
using MetaXpress 5 software and the Granularity application mod-
ule. The total granule area was used as an output parameter. Detailed
results of average, SD, Z0-factor coefficient, and assay window for
three compounds are given in Supplementary Table S7. Re-
presentative images and granularity analysis results from the au-
tophagy assay for rapamycin are shown in Figure
7A. We measured the dose response for several
representative compounds (chloroquine, verapa-
mil, and rapamycin) and determined their IC50
values in this assay. The measured fold increases
of autophagy staining were 4.7 for chloroquine,
2.1 for verapamil, and 1.4 for rapamycin, and
IC50s were determined to be 1.3, 33.5, and 3.1 mM
respectively.
Phospholipidosis, or excessive accumulation
of phosphilipids in tissues, is an important con-
cern for drug development, since many cationic
amphiphilic compounds can accumulate within
cells. This drug trapping is followed by a gradual
accumulation of drug-phospholipid complexes
(myeloid bodies) in tissues. Compounds including
antidepressants, antianginal, antimalarial, and
cholesterol-lowering drugs are reported to cause
drug-induced phospholipidosis. Drug-induced
phospholipidosis represents a concern as a safety
risk assessment; therefore, we have tested this
assay for utility in hepatotoxicity screening. We
used the LipidTOX reagent to evaluate the effects
of several compounds known to cause phospho-
lipidosis. iCell hepatocytes were treated with
compound for 48 h, at which time phospholipi-
dosis and steatosis were detected using the Li-
pidTOX reagent. A significant amount of neutral
lipids and phospholipid granules were observed
using the phospholipidosis assay, an example of
which is shown for the case of proproanolol
treatment in Figure 7B. Images were analyzed
using the Granularity application module of
MetaXpress 5 software with the total granule area
used as the output parameter. Detailed results of average, SD, Z0-
factor coefficient, and assay window for three compounds are given
in Supplementary Table S8. It was found that untreated hepatocytes
had significant background levels of neutral lipids and phospholip-
ids, which limited the capability of the assay. We were only able to
detect modest increases of total lipids or phospholipids in response
to compound treatment for total granule area or intensity in com-
parison to control (see line graph in Fig. 7B). The measured fold
increases of phospholipidosis were 2.4–3.7· for amiodarone, 2· for
cyclosporine, 1.4· for tamoxifen, and 4.5· for propranolol.
Multiparameter Hepatotoxicity Assay
A combination of the general toxicity assessment by the multi-dye
assay (Fig. 2) and mechanism specific JC-10 assay (Fig. 6) were
chosen to perform a Multiparameter Hepatotoxicity assay and screen
a small compound library. A customized analysis was setup for the
first assay using the MetaXpress 5 software CME, which allows the
image analysis to be tailored and optimized for multiparametric
outputs from toxicity indicators. This is important because it is
Fig. 5. Cytoskeleton integrity assessment by actin staining. (A) iCell hepatocytes treated
with 30 mM of aflatoxin B1 for 72 h, then fixed and stained with AlexaFluor-488-Phal-
loidin and Hoechst 33258. (B) Concentration-dependent responses for several
compounds using ‘‘number of actin-positive cells’’ as a readout. The IC50s for the tested
compounds were aflatoxin G1 (red squares), 1.9 mM; staurosporine (orange diamonds),
2.0mM; aflatoxin B1 (blue circles), 5.4 mM; idarubicin (grey squares), 7.4 mM; mitomycin
C (green triangles), 19 mM; and retinoic acid (purple circles), 480 mM.
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necessary to characterize the previously described multiple pheno-
typic changes that occur during hepatotoxicity to provide insight
into the specific mechanism of toxicity. The simultaneous analysis of
parameters provides a simple and efficient way to increase the
amount and quality of information provided by the assay.
The CME algorithm involved number of steps described in the
Materials and Methods section. Representative images and masks
derived from the analysis for untreated and amiodarone-treated cells
are shown in Supplementary Figure S1A. Shown are examples of cell
images and analysis masks representing cell area (spreading) and
nuclear characterization including
the results for Live Cell Area and
Apoptotic Cells. Multiple phenotypic
changes are easier to visualize using
compound profiles across multiple
parameters. Figure 8 presents the
profiles from several hepatotoxic
compounds from different groups
(cardiac drugs, anticancer drugs, an-
tibiotics, etc). Each compound has its
specific signature across the different
readouts. Importantly, the multipa-
rameter analysis allows for compar-
ing compound profiles and grouping
similar profiles together. In addition,





library was used for validation of
the multiparametric hepatotoxicity
(MPH) assays with iCell hepato-
cytes. As mentioned previously, the
phospholipidosis and autophagy
assays were found to be useful for
testing selected sets of individual
compounds, but because of the rel-
atively small assay windows ob-
served with these measures, we did
not use those assays for the library
screening. The MPH assay was as-
sessed according to assay sensitivity,
selectivity, and predictive value. For
the general toxicity assay cells were
incubated for 72 h with compounds
at concentrations of 1, 3, 10, 30, and
100 mM. Compounds were tested in
duplicates and different compound
concentrations were tested on sepa-
rate plates. For the mechanism spe-
cific assay ( JC-10) cells were treated
for 60 min at two concentrations, 10 and 100 mM. The output pa-
rameters that were used for the assessment were (1) number of
Calcein-positive cells; (2) number of MitoTracker-positive cells; (3)
total cell number; (4) average Calcein AM intensity; (5) total Calcein
AM cell area; (6) MitoTracker intensity; (7) MitoTracker cell area; (8)
average nuclear area; (9) nuclear average intensity; (10) JC-10
number of granules/cell; and (11) JC-10 total number of granules.
As described previously, the library included 240 hepatotoxic
compounds of which 30 were ‘‘safe compounds,’’ or negative con-
trols, and 2 were random blanks. The remaining 208 compounds were
Fig. 6. JC-10 assay for mitochondrial potential (MP). (A) iCell hepatocytes treated with indicated
compounds for 60 min. Top: Cells stained with Hoechst 33258 (nuclei), and JC-10 (MP); bottom:
overlay of Granularity analysis result masks. ‘‘Total’’ or ‘‘average number of granules per cell,’’
‘‘total granule area,’’ or ‘‘total granule intensity’’ were used as output parameters. (B) Con-
centration-dependent responses of ‘‘average number of granules per cell’’ for several compounds
and corresponding IC50 values (in mM): antimycin A (blue circles), 0.005; CCCP (red squares), 0.047;
valinomycin (green squares), 0.001; tolcapone (red triangles), 25.7; nefazodone (white circles),
33.6; leflunomide (purple diamonds), 34.3; ketoconazole (brown triangles), 71.4; isoniazid (grey
squares), n/d; fusariotoxin (orange circles), 132; and flutamide (blue triangles), 22.2.
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expected to be hepatotoxic, or ‘‘positive’’
based on known effects in clinical and
preclinical studies. In addition to the tested
compounds, each plate contained 48 wells
with same concentrations of DMSO. Assay
variability was determined from average
and SD of the DMSO controls and each
compound concentration.
The results acquired for all compounds
tested at 100 mM concentration are pre-
sented in Supplementary Figure S3A
and S3B. Averages from duplicates are
presented for the multiple read-outs. Com-
pounds are grouped into different com-
pound classes based on therapeutic
indication (not chemical similarity), based
on information provided by library de-
scription. Hits were classified as compounds
that caused effects greater than – 3 SD from
DMSO controls, and showed such effects in
more than one parameter. Compounds in-
dicated as hits in Supplementary Figure S3A
and S3B are highlighted in red (>3 SD de-
crease in each parameter as compared to the
appropriate DMSO control), or yellow ( > 3
SD increase in each parameter in compari-
son to the appropriate DMSO control). We
observed dose-dependent, incremental
changes for most of the parameters along
with an incremental increase in the number
of hits across the concentrations. However,
many hits were only detected at the highest
tested concentration (100 mM). Previous re-
ports have described hepatotoxicity effects
observed at 300 mM or even 1 mM concen-
trations. Our studies were limited by the
maximum DMSO concentration allowed.
We observed that 1% DMSO did not have an
impact on tested parameters while an in-
crease to 3% DMSO resulted in increased
variability (>20%) between read-outs from
control wells (data not shown). We have
tested concentration responses for individ-
ual selected compounds up to 1 mM. Among
compounds detected as hits were anticancer
drugs, neuroleptics, hormonal drugs, anti-
histamines, statins, cardiac drugs, anti-
fungal drugs, known toxins, and some
antibiotics and anti-inflammatory drugs.
Finally, we tested the potential for the
multiparametric endpoint data to rank
compounds for their potential hepato-
toxicity hazard based on concentration-
Fig. 7. (A) Autophagy detection assay. Image of iCell hepatocytes treated with rapamycin
for 24 h and stained with Cyto-ID autophagy detection kit. Right: Analysis with Granularity
module. (B) Phospholipidosis, lipid accumulation assay. Images of iCell hepatocytes
treated with propranolol for 48 h. Phospholipidosis and steatosis detected using LipidTOX
reagent showing phospholipids and neutral lipids as indicated. Concentration-dependent
responses for phospholipidosis using ‘‘total granular area’’ output and corresponding
IC50 values (in mM) for several compounds: amiodarone (blue circles), 18; cyclosporin
A (orange diamonds), 1.3; propranolol (green triangles), 25.7; and chloroquine (red
squares), 6.5.
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response in the iPSC-derived hepatocyte cell model. Because the
vehicle-only effect level was normalized across plates, we used four-
parameter maximum-likelihood logistic modeling to fit the data. In
accordance with the US EPA guidance for dose–response modeling28
we selected a one SD departure from the control mean as the
benchmark response from which a BMC is derived. If the maximum
response did not reach this level in the concentration range tested, the
‘‘no observable adverse effect level’’ was recorded as 100 mM, the
highest concentration used. Same curve fitting and BMC derivation
procedure was applied to all chemicals and endpoints collected. We
integrated multiple parameters collected in this study to rank che-
micals in the screened library for their overall relative safety rank
with respect to liver toxicity hazard (Fig. 8). Each compound’s BMC
values for 8 different parameters were analyzed and visualized us-
ing the ToxPi approach,29 which generates transparent graphical
rankings to facilitate decision making. The analysis of the data
showed that most nontoxic compounds were ranked high for
Relative Activity Index, while most hepatotoxic compounds were
ranked low. While in this analysis all parameters were given equal
weight, data integration assumptions may be amended in accor-
dance to the user’s needs and this analysis should be interpreted as
semi-quantitative.
DISCUSSION
There is a need for improved methods to evaluate in vitro toxicity
to meet the challenges associated with drug discovery and develop-
ment to the clinic. This is particularly true for hepatotoxicity,
which is a leading cause of compound failure during the pre-
clinical and clinical stages of development.4–6 High-content
imaging has been demonstrated to be particular useful for hep-
atotoxicity testing as it can assess subtle phenotypic changes
and provide multiparametric read outs.25,26 In the present work,
we have demonstrated the value of iPSC-derived hepatocytes for
this use in these types of assays. The morphological, marker
expression and functional characteristics exhibited are consis-
tent with those identified in primary hepatocytes (Fig. 1). In
addition, iPSC-derived hepatocytes are available in large quan-
tities, stable in culture, and display consistent, reproducible
performance.
We have further developed high-content analysis methods us-
ing this cell model. A number of phenotypic read-outs and output
parameters were characterized and a simple workflow assay pro-
tocol have been developed that can be used for defining general
and mechanism-specific toxicity of compounds. We have devel-
oped an automated multiparametric screening method and opti-
mized protocol for cell treatment, high-content imaging, and
image analysis. Using specific examples and a diverse set of hep-
atotoxic compounds we have demonstrated typical cell responses
and how different read-outs can be used in combination to char-
acterize different types of toxicity. In addition to its convenience,
this assay system has the potential for use in screening environ-
ments.
It is possible that other assays would be beneficial to, and
could even further increase, the overall predictivity of the sys-
tem. Two such assays were evaluated here: phospholipidosis and
autophagy. There were clear dose-dependent responses observed
with these assays, but improvements are needed to increase the
assay precision and robustness for them to be included in a full
screen. CYP450 expression or other read-outs relevant to metabolic
activity could further increase assay predictivity especially for the
compound classes mentioned above. This will be the subject of
future studies.
Future experiments will also focus on the use of specific pa-
tient-derived cell models for addressing idiosyncratic hepato-
toxicity. One of the great benefits of using iPSC-derived
hepatocytes is that they can be obtained from different patients
representing multiple genotypes. This affords the opportunity to
study the sensitivity of different genotypes to hepatotoxic com-
pounds and the prescreening of patients for potential adverse
liver reactions to drugs. This could also allow optimization of
drugs during development using SAR techniques for minimizing
hepatotoxicity.
The iPSC-hepatocyte cell model and high-content imaging-based
assays presented here show great promise for providing a highly
sensitive, specific, and predictive tool for assessing hepatotoxicity.
While a few limitations have been identified, further development of
the methods and models used will only increase the utility of this
important tool for the development of the next generation of ther-
apeutic compounds.
Fig. 8. Multiparametric hepatotoxicity analysis. ToxPi scores were used
to create a relative ranking of 240 screened compounds using multi-
parametric data (total cells, viable cells, cells with intact mitochondria,
area covered by live cells, mean area of live cells [cell spreading], mean
intensity of Calcein AM, nuclear mean area, and nuclear stain average
intensity). Yellow circles, nontoxic drugs; clear diamonds, hepatotoxic
drugs. Representative ToxPi-es for three compounds are shown to vi-
sualize the relative contribution of each parameter (represented in
colors of each slice) to the overall score. Note: Nontoxic compounds
are expected to align with a higher relative activity index value.
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